Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Francesco Schettini et al.|The Lancet Oncology|2019Cited by 193
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesIngrid Garberis, Magali Lacroix‐Triki, J. Linhart et al.|Nature Communications|2025Cited by 10
Deep Learning Allows Assessment of Risk of Metastatic Relapse from Invasive Breast Cancer Histological SlidesIngrid Garberis, Magali Lacroix‐Triki, V. Gaury et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 8
Abstract P1-16-01: Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA)Francesco Schettini, Daniele Generali, Carla Rognoni et al.|Cancer Research|2019Cited by 2